A5063221042- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Neuroendocrine Tumor Research Advances
- Bladder and Urothelial Cancer Treatments
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
- Immunotherapy and Immune Responses
- Urinary and Genital Oncology Studies
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Gastrointestinal Tumor Research and Treatment
- DNA Repair Mechanisms
- Peptidase Inhibition and Analysis
- BRCA gene mutations in cancer
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroblastoma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
University of Florida Health
2018-2025
Florida College
2021-2024
University of Florida
2018-2024
UF Health Cancer Center
2018-2024
UF Health Shands Hospital
2021
Memorial Sloan Kettering Cancer Center
2015
State University of New York
2014
Abstract Radiopharmaceuticals have been utilized for men with advanced prostate cancer decades. Older agents, seldom used today, provided palliation bone metastatic pain. In 2013, the alpha emitter radium-223 a catalyst field by prolonging survival in castrate-resistant (mCRPC). Recently radioisotopic therapies gained further interest development and FDA approval of 177 lutetium (177Lu)-PSMA-617 (also known as Lu-177 vipivotide tetraxetan). This agent targets prostate-specific membrane...
There have been significant advancements in precision medicine and approaches to medication selection based on pharmacogenetic results. With the availability of direct‐to‐consumer genetic testing growing awareness interindividual variability, patient demand for more precise, individually tailored drug regimens is increasing. The University Florida (UF) Health Precision Medicine Program (PMP) was established 2011 improve integration genomic data into clinical practice. In ensuing years, UF...
Background: Gallbladder carcinoma (GBC) is a rare, aggressive malignancy comprising 0.5% of gastrointestinal cancers. It has poor survival outcomes due to its insidious onset, lack standardized screening, and limited therapies. Advanced-stage diagnosis with liver, lymph node, peritoneal metastasis common, while bone rare. The knowledge on in GBC case reports small series, clinical significance largely unexplored. Methods: study extracted the demographic variables patients metastatic (M1)...
BRCA1-associated protein 1 (BAP1) is a critical cell cycle and DNA damage response (DDR) regulator with mutations (mBAP1) causing functional loss. PARP inhibitors (PARPis) demonstrate synthetic lethality in mBAP1 preclinical models, independent of underlying BRCA status. This study aimed to explore the clinical activity niraparib patients advanced tumors likely harbor mBAP1.
839 Background: Circulating tumor DNA (ctDNA) is a promising tool for monitoring treatment response but challenged by pan-cancer quantification and consistent outcome correlations. Northstar Response (NSR) quantifies >500 cancer specific methylated loci, offering reflection of disease burden clinical response. Methods: We present prospective observational study to evaluate the utility NSR. Patients with advanced GI cancers had serial ctDNA assessed at baseline during systemic correlations...
3122 Background: BRCA1-Associated Protein 1 (BAP1) acts as a tumor suppressor and critical regulator of the cell cycle DNA damage response (DDR). PARP inhibitors (PARPi) demonstrate synthetic lethality in BAP1 mutant (mBAP1) preclinical models, independent underlying germline BRCA status. mBAP1 leads to loss functional protein several solid tumors. This study aimed explore clinical activity niraparib patients (pts) with advanced tumors likely harbor mBAP1. Methods: Eligible adult pts...
The University of Florida Health conducted a pragmatic implementation pharmacogenetics (PGx) panel-based test to guide medications used for supportive care prescribed patients undergoing chemotherapy. was in the context clinical trial with non-hematologic cancers being treated Patients were randomized either intervention arm or control and received PGx testing immediately at end study, respectively. completed MD Anderson Symptom Inventory (MDASI) assess quality life (QoL). A total 150...
<h3>Importance</h3> The introduction of biosimilars and novel delivery devices between 2014 2019 may have changed the utilization granulocyte colony-stimulating factors (G-CSF). <h3>Objective</h3> To assess trends G-CSFs for primary prophylaxis febrile neutropenia (FN) among patients with cancer receiving myelosuppressive chemotherapy commercial or Medicare insurance. <h3>Design, Setting, Participants</h3> This cross-sectional study assessed G-CSF overall stratified by regimen risk level....
Advanced hepatocellular carcinoma (HCC) generally has a dismal prognosis. Bone metastases from HCC are infrequent, with poorer However, the survival influencing factors not yet well understood.The aim of present study was to assess clinical features and tumor characteristics patients bone metastasis.A cohort 170,576 adult studied using National Cancer Database (NCDB) spanning 2010 2019, within this group, 5285 (3.1%) were diagnosed metastasis. We performed Kaplan-Meier method calculate...
655 Background: Neoadjuvant treatment for resectable pancreatic cancer (PDAC) is increasing in acceptability, but a standard regimen has yet to be established. The modified FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin and irinotecan) often requires dose modifications, delays growth factor support due toxicity. Liposomal irinotecan injection (Nal-IRI) FDA-approved with well-tolerated safety profile relapsed, refractory mPDAC. This current study substitutes Nal-IRI traditional the...
e24128 Background: The combination therapy of an immune checkpoint inhibitor (ICI) with a vascular endothelial growth factor receptor tyrosine kinase (VEGFR-TKI) is considered first line treatment option for patients metastatic clear cell renal carcinoma (ccRCC). TKI-induced hypertension well-known potential side effect VEGFR-TKIs however little known about the real-world increase in systolic blood pressure (SBP) and diastolic (DBP) without underlying treated this therapy. Methods: A...
Abstract: The treatment paradigm for high risk localized and advanced kidney cancer has been characterized by ongoing changes, with the introduction of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) later immune checkpoint blockade. In this article, we review how current evidence informs our decision-making on post-checkpoint inhibitor systemic therapies, role adjuvant and/or neoadjuvant cytoreductive nephrectomy in evolving therapy landscape. While some...
Recent literature suggests an increasing use of systemic treatment in patients with advanced cancer near the end life (EOL), partially driven by adoption immune checkpoint inhibitors (ICIs). While studies have identified this trend, additional variables associated ICI at EOL are limited. Our aim was to characterize a population who received dose last 30 days life.We performed manual retrospective chart review ≥ 18 years died within receiving ICI. Metrics such as Eastern Cooperative Oncology...
Trastuzumab-deruxtecan (T-DXd) is a novel antibody drug conjugate that has improved treatment outcomes in patients with ERBB2-positive cancer, including locally advanced or metastatic gastric and gastro-oesophageal junction adenocarcinoma. One of the reported side effects this medication drug-induced pneumonitis. We present case report, diagnostic dilemma patient presenting clinical radiographical features pneumonitis but was found to have pneumocystis jirovecii pneumonia (PJP). Our first...
Important progress has been made over the last decade in classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although options available patients well-differentiated tumors (NETs) have greatly expanded, rapidly changing landscape presented unanswered questions about how best to optimize, sequence, individualize therapy. Perhaps most important development approval 177Lu-DOTATATE gastroenteropancreatic-NETs, raising around optimal...
Abstract Lessons Learned Treatment for patients with metastatic colorectal cancer (mCRC) typically involves multiple lines of therapy eventual development treatment resistance. In this single-arm, phase II study involving heavily pretreated patients, the combination sorafenib and capecitabine yielded a clinically meaningful progression-free survival 6.2 months an acceptable toxicity profile. This oral doublet is worthy continued investigation clinical use in mCRC. Background Capecitabine...
For patients with localized pancreatic cancer minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy. FOLFIRINOX is combination chemotherapy regimen that offers promising results in the perioperative metastatic settings; however, it can cause significant adverse effects. Such toxicity negatively impact some patients, resulting discontinuation or unsuitability. In an effort to reduce toxicities optimize...
Objectives: The objectives of this study was (1) to examine the representation women in clinical trials for systemic therapy muscle-invasive (MIBC) or metastatic bladder cancer (BC) and (2) determine association between sex treatment MIBC BC. Methods: A review cited by National Comprehensive Cancer Network guidelines performed. Proportions were compared with corresponding proportions US population 1975 2018, based on Surveillance, Epidemiology, End Results database. We also used Database...